Actoxumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | Clostridium difficile |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number | 1245634-25-6 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6476H10000N1740O2010S45 |
| Molar mass | 145.9 kg/mol |
Actoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridium difficile infection.[1]
This drug, along with bezlotoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School.[2] The project was then licensed to Merck & Co., Inc. for further development and commercialization.[3]
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council - Actoxumab" (PDF). American Medical Association.
- ↑ Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Leney M, Sloan S, Hay CA, Ambrosino DM (January 2010). "Treatment with monoclonal antibodies against Clostridium difficile toxins". N. Engl. J. Med. 362 (3): 197–205. doi:10.1056/NEJMoa0907635. PMID 20089970.
- ↑ "Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusive Licensing Agreement for Investigational Monoclonal Antibody Combination for Clostridium Difficile Infection". Press Release. Merck Sharp & Dohme Corp.
This article is issued from Wikipedia - version of the 5/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.